October 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
The biomarker test measures NfL levels through standard blood collection.
The phase 3 CHAMPION-NMOSD trial evaluated ravulizumab-cwvz, a C5 complement inhibitor, in 58 adults with AQP4 Ab+ NMOSD.
Feeling like ‘in a fog’ and sadness may predict symptoms lasting 28 days or longer following a sport-related concussion
SPN-830 provides a continuous subcutaneous infusion of apomorphine through an infusion pump.
The recalled lots of Levetiracetam Injection 500mg per 5mL; NDC Number 25021-780-05, were distributed nationwide from March to November 2021.
Eprontia is approved for the treatment of partial-onset or primary generalized tonic-clonic seizures and migraine prevention.
History of TBI tied to 52 percent increased odds of prescription opioid use, 65 percent increased odds of prescription opioid misuse
The system works with Medtronic’s Percept™ PC Neurostimulator.
Using the programmer app, clinicians are able to remotely prescribe new treatment settings to the patient’s neuromodulation device via cloud and Bluetooth-based technology.